Eli Lilly Reports the P-III (SURMOUNT-OSA) Study Data of Tirzepatide in Patients with Obstructive Sleep Apnea (OSA) and Obesity
Shots:
- The P-III (SURMOUNT-OSA) trial assessed the safety & efficacy of tirzepatide (10mg or 15mg, QW) vs PBO to treat moderate-to-severe OSA & obesity adults under which study 1 was for those not using PAP therapy while study 2 was for those using & continuing PAP therapy
- The study 1 results demonstrated a reduction in the mean AHI of 27.4 vs 4.8 events per hour while the 2EPs showed a reduced mean AHI of 55.0% vs 5.0% and a reduced mean body weight of 18.1% vs 1.3% from baseline to 52wks.
- Furthermore, the study 2 results demonstrated a reduction in the mean AHI of 30.4 vs 6.0 events per hour while the 2EPs showed a reduced mean AHI of 62.8% vs 6.4% and a reduced mean body weight of 20.1% vs 2.3% from baseline to 52wks.
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly’s Zepbound (tirzepatide) Receives the US FDA’s Approval as a Treatment for Obesity or Overweight
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
